Table 2.
Tocotrienol intake and risk of breast cancer-specific death/recurrence in women with early breast cancer and estrogen receptor-positive tumors receiving tamoxifen
| Type of treatment received along with tamoxifen | ||
|---|---|---|
| Placebo (n = 120) | Tocotrienol (n = 120) | |
| Breast cancer-related death | ||
| Number of patients (n (%)) | 6 (5.0) | 2 (1.7) |
| Crude hazard ratio | 1.00 | 0.33 (95% CI, 0.07 to 1.61) |
| Adjusted hazard ratioa | 1.00 | 0.40 (95% CI, 0.08 to 2.05) |
| Local/systemic recurrence of breast cancer | ||
| Number of patients (n (%)) | 20 (16.7) | 16 (13.3) |
| Crude hazard ratio | 1.00 | 0.80 (95% CI, 0.41 to 1.54) |
| Adjusted hazard ratioa | 1.00 | 0.84 (95% CI, 0.43 to 1.65) |
aAdjusted for age (continuous), ethnicity (Malay, Chinese, Indian), TNM stage (stage 1, stage 2), and lymph node involvement (yes, no).